Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 5/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7328910 | 0.84 | REN (0.52) | ALDH1A1KMT2ARENMETAP2CYP1A2 | |
| SCHEMBL7326084 | 0.84 | REN (0.52) | ALDH1A1KMT2ARENMETAP2CYP1A2 | |
| SCHEMBL12036061 | 0.84 | REN (0.40) | ALDH1A1KMT2ARENSHBGMETAP2 | |
| Hydrochloric Acid SCHEMBL7324277 | 0.82 | REN (0.51) | ALDH1A1KMT2ARENMETAP2CYP1A2 | |
| SCHEMBL6145227 | 0.81 | SHBG (0.41) | ALDH1A1KMT2ARENSHBGMETAP2 | |
| SCHEMBL6662787 | 0.81 | SHBG (0.41) | ALDH1A1KMT2ARENSHBGMETAP2 | |
| SCHEMBL13169085 | 0.81 | TP53 (0.39) | RENKDM4E | |
| SCHEMBL21409652 | 0.79 | SHBG (0.37) | ALDH1A1KMT2ARENSHBGMETAP2 | |
| SCHEMBL1105462 | 0.79 | SHBG (0.37) | ALDH1A1KMT2ARENSHBGMETAP2 | |
| SCHEMBL7327138 | 0.76 | REN (0.47) | ALDH1A1KMT2AREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | ALDH1A1 1989/4885KMT2A 3420/4885REN 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.